The Biden Admin Is Shaking Down Fixed-Income Seniors

Visualize accompanying your elderly parent to the pharmacy to renew their prescription and realizing that not only is the medication not covered by their plan, but the cost has surged by 1,900 percent. You knew inflation was problematic, but this is different. Unfortunately, this upsetting situation might become a reality for numerous Americans due to a lesser-known section of the ironically named Inflation Reduction Act.

Many Americans are unaware that the Inflation Reduction Act granted the Department of Health and Human Services (HHS) the power to predetermine Medicare’s prices for a select list of medications. A pharmaceutical manufacturer has 30 days to provide extensive internal data to HHS, and then HHS responds with a “maximum fair price.” However, if the government and a drug company fail to reach an agreement on price, the company faces two options: comply with the price, potentially resulting in substantial financial loss as they sell the medication, or act as an enforcer of the IRS by imposing and collecting a 95 percent excise tax, not just for Medicare, but for all drug sales.

As a health insurance broker who negotiates with insurance companies and healthcare providers, I constantly seek avenues for employers, their employees, and consumers to manage their financial and health risks. However, when the government deprives individuals of access to necessary medications, it imperils their well-being and raises the likelihood of hospitalization or death. It also hinders insurance brokers’ ability to find plans that suit our clients’ specific requirements.

This new policy is essentially a price control disguised as a negotiation. Coercing a company with sanctions and employing an “or else” approach isn’t negotiation, it’s intimidation. The federal government acknowledges this because pharmaceutical companies already haggle prices with employers and insurance companies and present numerous discounts and rebates, including programs to offer medications at reduced costs or with no copay.

This policy will not only impact wealthy drug companies. Situations like the previously mentioned scenario will severely affect numerous fixed-income seniors if the medications they rely on slip through the negotiation process. Medicare recipients grappling with diabetes (nearly 1 in 5 Americans over age 65), confronting the risk of stroke (which claims one American life every 3 minutes and 14 seconds), or battling cancer will be obliged to pay out of pocket until the manufacturer complies. It’s not an exaggeration to say this policy will have deadly consequences.

In August, the IRS released guidelines on implementing this excise tax, and independent legal analysis confirms that the excise tax commences at 95 percent but could escalate to up to 1,900 percent of the drug’s price. Yes, the Democrats’ strategy to reduce drug prices entails trying to enforce a specific price on a pharmaceutical company and, if that fails, imposing a heavy tax on those who need the medication, similar to the government’s taxation of cigarettes, beer, and liquor. Only in Washington could compelling the industry to carry out the IRS’s problematic tasks be labeled as a “negotiation” to lower prices. This new policy could accurately be described as “price control,” a redistributive policy that curtails the available supply for consumers.

Economists generally oppose price controls because when governments, lacking insight into an industry, intervene to set prices completely divorced from reality, they eliminate the profit motive for entrepreneurs and wealth-creators to innovate and invest. This results in a significant misallocation of resources — in this case, a scarcity. Companies curtail their losses and cease production, leaving individuals in need of their products unable to obtain them at any price.

Leaders from both political parties widely acknowledge that reducing prescription medication prices is a crucial national priority, despite differing methods in achieving it. It’s crucial to avoid causing harm while figuring out the specifics. Unfortunately, policies that elevate prices and don’t reduce inflation appear to be the administration’s primary approach.

Meanwhile, incredibly, this legalized pressure is persistently referred to as “negotiation.” It brings to mind the iconic words of the “Princess Bride” character Inigo Montoya: “You keep using that word. I do not think it means what you think it means.”

More Reading

Post navigation

Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *